1 September 2024
Investor Webinar - Starpharma Business Update
Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update.
Starpharma’s CEO, Cheryl Maley, hosted the webinar, alongside the CFO and Company Secretary, Justin Cahill, VP of Business Development, Dr Tony Eglezos, and VP of Development and Regulatory Affairs, Dr Jeremy Paull.
This webinar may include forward-looking statements. Please see below our standard disclaimer.
View/download the presentation here.
View/download the ASX Announcement, 'Starpharma Business Update', here.
Important Notice and Disclaimer
This document is intended for investors and market participants only. This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, “outlook” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of any Starpharma product. This document is intended for people seeking information about Starpharma for investment and business purposes. This document contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Nothing contained in this document should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information in this document is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.